ABSTRACT
BACKGROUND Congenital mitral valve disease (CMVD) presents major challenges in medical and surgical management. Data on predictors of mitral valve (MV) reoperation and value of 3D echocardiography (3DE) in this context are currently limited. Aim of our study was to identify predictors of MV reoperation and to investigate the value of 3DE in risk stratification.
METHODS All children <18 years old who underwent MV reconstruction for CMVD from 2002 to 2018 were included. Pre and postoperative 2D-echocardiogram (2DE) and 3DE data were collected. Competing risks and Cox regression analyses were used to identify independent predictors of MV reoperation. Receiver operating characteristics curve (ROC) analysis was used to assess the predictive values of 3DE versus 2DE. Decision tree analysis was used to compute decision algorithms.
RESULTS Over the course of the study period, 206 children underwent MV reconstruction for CMVD: 105 had mitral stenosis (MS), 75 had mitral regurgitation (MR), and 26 had mixed disease (MD). Of them, 64 (31%) required a MV-reoperation. At multivariable analysis, age <1 year (hazard ratio [HR]=2.65; 95% confidence interval [CI]:1.13-6.21), tethered leaflets (HR=2.00; 95% CI:1.05- 3.82;), moderate or greater 2DE postoperative MR (HR=4.26; 95% CI:2.45-7.4), as well as changes in 3D-effective orifice area (3D-EOA) and in 3D-vena contracta regurgitant area (3D-VCRA) were all found to be independent predictors of MV reoperation. By ROC analysis, changes in 3D-EOA and 3D-VCRA were found to have significantly higher predictive value than changes in mean gradients (AUC=0.847 vs AUC=0.676, P=0.006) and 2D-VCRA (AUC=0.969 vs AUC=0.720, P=0.012), respectively. Decision-tree analysis found that a <30% increase in 3D-EOA had 80% accuracy (HR=8.50; 95% CI:2.9-25.1) and a <40% decrease in 3D-VCRA had 93% accuracy (HR=22.50; 95% CI:2.9-175) in predicting MV reoperation for stenotic and regurgitant MV, respectively.
CONCLUSIONS Age <1 year, tethered leaflets, 2DE postoperative MR, changes in 3D-EOA and 3D-VCRA were all independent predictors of MV-reoperation. 3DE parameters had higher predictive value than 2DE. 3DE-based decision-tree algorithms may help risk stratification and serve as a support tool for clinical decision-making in patients with CMVD.
In congenital mitral valve (MV) disease patients undergoing MV reconstruction, changes in 3D effective orifice area (3D-EOA) and 3D vena contracta regurgitant area (3D-VCRA) were found to be independent predictors of MV reoperation.
Changes in 3D effective orifice area (3D-EOA) and 3D vena contracta regurgitant area (3D-VCRA) had significantly higher predictive value compared to 2D-echocardiography parameters, i.e. changes in mean gradient, 2D-VCRA and moderate or greater postoperative 2D mitral regurgitation.
Decision tree analysis identified cut-off points in changes of 3D-EOA and 3D-VCRA to predict MV reoperation.
Changes in 3D-EOA and 3D-VCRA can be measured in the operating room to consider return to bypass, or at discharge, to help inform need for early follow-up and MV reoperation.
3DE-based decision tree predictive algorithms may help in risk stratification and serve as a support tool to facilitate clinical decision-making.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Nora Lang received the Kaplan Meier Fellowship and a fellowship from the German Research Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board at Boston Children's Hospital approved the study with a waiver for informed consent (IRB-P00023266).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.
NON-STANDARD ABBREVIATIONS AND ACRONYMS
- 2DE
- 2-dimensional echocardiography
- 3DE
- 3-dimensional echocardiography
- AUC
- area under the curve
- CI
- confidence interval
- EOA
- effective orifice area
- HLHS
- hypoplastic left heart syndrome
- HR
- hazard ratio
- IQR
- interquartile range
- LVEDP
- left ventricular end diastolic pressure
- MD
- mixed disease
- MR
- mitralregurgitation
- MS
- mitral stenosis
- MV
- mitral valve
- N
- number
- ROC
- receiver operating characteristic
- VCRA
- vena contracta regurgitant area
